Judge Says Apotex Generic Doesn't Infringe Cephalon Patent

Law360, New York (March 30, 2012, 3:49 PM EDT) -- A Pennsylvania federal judge on Wednesday said an abbreviated new drug application by Apotex, Inc. does not infringe Cephalon Inc.’s patent for its narcolepsy drug Provigil, finding Apotex’s method for producing its proposed generic differs from Cephalon’s process.

U.S. District Judge Mitchell S. Goldberg ruled that Cephalon failed to prove that a milling procedure designed to reduce the size of particles that make up Apotex’s proposed version of Provigil alters the medication to such a degree that that it infringes on Cephalon’s patent.

Judge Goldberg held...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.